ORGANIC LETTERS

2003
Vol. 5, No. 16
2837−2839

Synthetic Studies Directed toward the Assembly of the *C*-Glycoside Fragment of the Telomerase Inhibitor D8646-2-6

Akira Kanai,[†,‡] Tomoyuki Kamino,[†,‡] Kouji Kuramochi,[‡] and Susumu Kobayashi*[,†,‡]

Frontier Research Center for Genomic Drug Discovery and Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Nodashi, Chiba 278-8510, Japan

kobayash@rs.noda.tus.ac.jp

Received May 19, 2003

ABSTRACT



Construction and characterization of the C-glycosidic moiety of telomerase inhibitor D8646-2-6 (1) are described. This is the first example of the C-glycosylation using electron-poor aromatics, 4-hydroxypyrone, as a glycosyl acceptor. The glycosylation reaction and base-promoted isomerization affords desired *β*-*C*-glycoside in a 61% overall yield.

D8646-2-6 (**1**) was isolated as an inhibitor of telomerase from the culture broth of *Epicoccum purpurascens* by the Mitsubishi Pharma Corporation group.[1] It has a unique C^3-pyranosyl 4-hydroxypyrone structure with a conjugated heptaene side chain. The relative and absolute stereochemistry of **1** have not been determined. Analysis of the reported ^{1}H NMR data of **1** strongly suggests a C^3-*β*-galactopyranosyl-4-hydroxypyrone structure, although the chirality of the two centers in the side chain is not known. The galactopyranosyl-4-hydroxypyrone structure is quite interesting when compared to *C*-glycosides containing phenol or naphthol derivatives as aryl units.[2] There are some examples of 4-hydroxypyrones connected to a 4-deoxyglucose as sugar moiety, and most of them have antifungal activity.[3] The most challenging step in the synthesis of **1** involves the construction of the pyranosyl 4-hydroxypyrone moiety. The α-pyrone moieties of meroterpenoids (mixed polyketide−terpenoid metabolites) are usually constructed by the cyclization of the corresponding *β*,*δ*-diketo esters.[4] A similar strategy involving the cyclization of α-*C*-pyranosyl *β*,*δ*-diketo ester, which could

[†] Faculty of Pharmaceutical Sciences.
[‡] Frontier Research Center for Genomic Drug Discovery.

(1) Kimura, J.; Furui, M.; Kanda, M.; Sugiyama, M. *Jpn. Kokai Tokkyo Koho* **2002**, 8 (in Japanese).

(2) For reviews on aryl *C*-glycosides, see: (a) Jaramillo, C.; Knapp, S. *Synthesis* **1994**, 1. (b) Hacksell, U.; Davis, G. D., Jr. *Prog. Med. Chem.* **1985**, *22*, 1. (c) Suzuki, K.; Matsumoto, T. In *Recent Progress in the Chemical Synthesis of Antibiotics and Related Microbial Products*; Lukacs, G., Ed.; Springer: Berlin, 1993; Vol. 2, p 353. For isolation and structure determination of *C*-glycosides, see: (a) Ayer, W. A.; Kawahara, N. *Tetrahedron Lett.* **1995**, *36*, 7953. (b) Hochlowski, J. E.; Whittern, D. N.; Buko, A.; Alder, L.; McAlpine, J. B. *J. Antibiot.* **1995**, *48*, 614. (c) Saijo, R.; Nonaka, G.; Nishioka, I.; Chen, I.-S.; Hwang, T.-H. *Chem. Pharm. Bull.* **1989**, *37*, 2940. (d) Imamura, N.; Kakinuma, K.; Ikekawa, N.; Tanaka, H.; Omura, S. *J. Antibiot.* **1981**, *34*, 1517. (e) Traxler, P.; Fritz, H.; Fuhrer, H.; Richter, W. J. *J. Antibiot.* **1980**, *33*, 967.

(3) (a) Namikoshi, M.; Kobayashi, H.; Yoshimoto, T.; Meguro, S.; Akano, K. *Chem. Pharm. Bull.* **2000**, *48*, 1452. (b) Evidente, A.; Conti, L.; Altomare, C.; Bottalico, A.; Sindona, G.; Segre, A. L.; Logrieco, A. *Nat. Toxins* **1994**, *2*, 4. (c) Xaio, J.-Z.; Kumazawa, S.; Yoshikawa, N.; Mikawa, T.; Sato, Y. *J. Antibiot.* **1993**, *46*, 48.

(4) (a) Hagiwara, H.; Kobayashi, K.; Miya, S.; Hoshi, T.; Suzuki, T.; Ando, M.; Okamoto, T.; Kobayashi, M.; Yamamoto, I.; Ohtsubo, S.; Kato, M.; Uda, H. *J. Org. Chem.* **2002**, *67*, 5969. (b) Zhang, F.; Danishefsky, S. *J. Angew. Chem., Int. Ed.* **2002**, *41*, 1434.

10.1021/ol034873k CCC: $25.00
Published on Web 07/08/2003



Figure 1. Structure of D8646-2-6 and some examples that contained deoxyglucose as a sugar moiety.

be readily prepared by C-glycosylation of β-ketoester or malonate,[5] might seem like an obvious synthetic route. However, a direct coupling of 4-hydroxypyrone to the sugar moiety is desirable for establishing a convergent and efficient methodology. Despite extensive studies into the C-glycosylation of electron-rich aromatics,[6] there have been no reports concerning C-glycosylation of 4-hydroxypyrone. During the course of our investigations into the synthesis of **1**, we studied the reaction of 4-hydroxypyrone and galactose derivatives. The results of these experiments are described in this paper.

We examined coupling of *O*-(2,3,4,6-tetra-*O*-acetyl-β-D-galactopyranosyl)trichloracetimidate **2**[7] to 4-hydroxy-6-methylpyrone **3** or its TMS ether **4**[8] (Scheme 1). In both

Scheme 1. Glycosylation Reaction between the Trichloroacetimidate **2** and Pyrones **3** and **4**



cases O-glycosylation proceeded smoothly in the presence of TMSOTf in CH_2Cl_2 affording β-*O*-glycoside **5**[9] in high yield (90% for **3** and 87% for **4**), but we could not detect the formation of the desired *C*-glycoside. With an excellent methodology developed by Suzuki in mind, we also attempted an *O*→*C* glycosyl rearrangement[10] of **5** by treatment with Lewis acid. Despite varying the reaction conditions (TMSOTf in CH_2Cl_2, $BF_3{\cdot}OEt_2$ in CH_2Cl_2, $AgClO_4$ in CH_2Cl_2, etc.), none of the desired *C*-glycoside was obtained and, in most cases, almost all of the starting material **5** was recovered. The low reactivity of the *O*→*C* rearrangement could be due to electron-withdrawing acetoxy group at C-2 in **5**. This led us to employ an *O*-benzyl-protected galactose derivative as the glycosyl donor. After a systematic survey of glycosyl acceptors (4-OBn pyrone, 4-OMe pyrone, 4-OTMS pyrone), Lewis acids, and solvents (TMSOTf in CH_2Cl_2/CH_3CN, $BF_3{\cdot}OEt_2$ in CH_2Cl_2/CH_3CN, $SnCl_4$ in CH_2Cl_2, $AlCl_3$ in CH_2Cl_2), we obtained a mixture of both *C*-glycosides (**7** and **8**) and *O*-glycosides (**9** and **10**) by treatment of tetra-*O*-benzyl-D-galactopyranosyl fluoride **6**[11] with 4-hydroxy-6-methylpyrone **3** in the presence of $BF_3{\cdot}OEt_2$ in CH_2Cl_2 (Table 1, entry 1). The structures of the *C*-glycosides **7** and **8** were established by ^{1}H NMR analysis. The anomeric proton of the minor glycoside **8** appeared at δ 4.71 with $J = 9.4$ Hz allowing us to determine the β-*C*-glycoside structure. The α-*C*-glycoside structure of the major isomer **7** could not be unambiguously determined from the chemical shift and the coupling constant of the anomeric proton (δ 5.25 as a singlet). However, the strong NOE (7%) between

Table 1. Glycosylation Reaction between the Galactosyl Fluoride **6** and Pyrones **3** and **4**



entry	pyrone (equiv)	$BF_3{\cdot}OEt_2$ (equiv)	solvent	yield (%)		
1	**3** (1)	1	CH_2Cl_2	**7** (15)	**8** (8)	**9**, **10** (15)
2	**3** (3)	1	CH_2Cl_2	**7** (47)	**8** (1)	**9**, **10** (7)
3	**3** (5)	1	CH_2Cl_2	**7** (56)	**8** (5)	**9**, **10** (20)
4	**3** (10)	1	CH_2Cl_2	**7** (54)	**8** (4)	**9**, **10** (21)
5	**3** (5)	1	CH_3CN	**7** (9)	**8** (14)	**9**, **10** (2)
6	**3** (10)	3	CH_3CN	**7** (21)	**8** (16)	**9**, **10** (8)
7	**3** (10)	3	CH_2Cl_2	**7** (36)	**8** (7)	**9**, **10** (37)
8	**4** (5)	1	CH_2Cl_2	**7** (40)	**8** (3)	**9**, **10** (38)
9	**4** (10)	1	CH_2Cl_2	**7** (32)	**8** (trace)	**9**, **10** (46)

(5) (a) Gervay, J.; Hadd, M. J. *J. Org. Chem.* **1997**, *62*, 6961. (b) Allevi, P.; Anastasia, M.; Ciuffreda, P.; Fiecchi, A.; Scala, A. *J. Chem. Soc., Perkin Trans. 1* **1989**, 1275. (c) Stewart, A. O.; Williams, R. M. *J. Am. Chem. Soc.* **1985**, *107*, 4289. (d) Hanessian, S.; Pernet, A. G. Can. *J. Chem.* **1974**, *52*, 1266.

(6) (a) Kometani, T.; Kondo, H.; Fujimori, Y. *Synthesis* **1988**, 1005. (b) Rasolojaona, L.; Mastagli, P. *Carbohydr. Res.* **1985**, *143*, 246−248. (c) Schmidt, R. R.; Hoffmann, M. *Tetrahedron Lett.* **1982**, *23*, 409−412. (d) Eade, R. A.; Pham, H.-P. Aust. *J. Chem.* **1979**, *32*, 2483.

(7) (a) Upreti, M.; Ruhela, D.; Vishwakarma, R. A. *Tetrahedron* **2000**, *56*, 6577. (b) Kluge, M.; Schneider, B.; Sicker, D. *Carbohydr. Res.* **1997**, *298*, 147.

(8) (a) Bonsignore, L.; Cabiddu, S.; Loy, G.; Secci, D. *Heterocycles* **1989**, *29*, 913. (b) Ziegler, T.; Layh, M.; Effenberger, F. *Chem. Ber.* **1987**, *120*, 1347. (c) Effenberger, F.; Ziegler, T.; Schönwäelder, K.-H.; Kesmarszky, T.; Bauer, B. *Chem. Ber.* **1986**, *119*, 3394.

(9) Anomeric proton of **5** appeared at δ 5.20 with $J = 7.9$ Hz.

(10) (a) Suzuki, K. *Pure Appl. Chem.* **1994**, *66*, 2175. (b) Matsumoto, T.; Katsuki, M.; Jona, H.; Suzuki, K. *J. Am. Chem. Soc.* **1991**, *113*, 6982. (c) Matsumoto, T.; Hosoya, T.; Suzuki, K. *Tetrahedron Lett.* **1990**, *31*, 4629. (d) Matsumoto, T.; Katsuki, M.; Jona, H.; Suzuki, K. *Tetrahedron Lett.* **1989**, *30*, 6185. (e) Matsumoto, T.; Katsuki, M.; Suzuki, K. *Tetrahedron Lett.* **1988**, *29*, 6935.

(11) (a) Kanie, O.; Ito, Y.; Ogawa, T. *Tetrahedron Lett.* **1996**, *37*, 4551. (b) Nicolaou, K. C.; Mitchell, H. J. *Angew. Chem., Int. Ed.* **2001**, *40*, 1576.

H-1′ and H-2′ and the NOE (8%) between H-1′ and H-6′ unambiguously established the stereochemistry, which indicates that the α-*C*-glycoside **7** adopts the $^1C_4$ conformation with the equatorially oriented pyrone moiety. The yield of *C*-glycoside was improved by using an excess amount of pyrone **3** (Table 1, entry 1−4). In acetonitrile, C-glycosylation did not proceed well, but the desired *β*-*C*-glycoside was obtained in higher yield than in CH_2Cl_2. We think that this selectivity is due to the nitrile effect.[12] When TMS-protected pyrone **4** was used, a considerable amount of O-glycosylation products were formed (Table 1, entry 8−9).

To determine whether *C*-glycoside was formed via *O*-glycoside, **9** and **10** were separately treated with $BF_3{\cdot}OEt_2$ in CH_2Cl_2 (Scheme 2). Interestingly, both **9** and **10** afforded

Scheme 2. Attempted *O*→*C* Glycosyl Rearrangement



S.M.	Yield (%)		Recovered S.M.(%)
9	**7** (9)	**8** (0)	39
10	**7** (trace)	**8** (1)	66

only a trace amount of *C*-glycoside. Therefore, C-glycosylation and O-glycosylation compete in the case of 4-hydroxypyrone. These results are quite different from glycosylation reactions involving electron-rich aromatics.

The results also show that the Fries-type rearrangement, which proceeded during acylation of 4-hydroxypyrone, did not occur.[13]

Although the desired *β*-*C*-glycoside was produced as a minor isomer, we found that the α-*C*-glycoside **7** underwent ready and quantitative isomerization[5a,14] with DBU in refluxing THF. Isomerization probably proceeds via base-promoted ring-opening followed by recyclization, giving the thermodynamically more stable *β*-isomer (Scheme 3).

Scheme 3. Isomerization of **7** to **8**



Finally, it was necessary to deprotect **8**. Hydrogenolysis of **8** with $Pd(OH)_2-H_2$ in THF provided **11** in 65% yield (Scheme 4). The ^{1}H NMR and ^{13}C NMR spectral data of **11**

Scheme 4. Hydrogenolysis of the *C*-Glycoside **8**



in CD_3OD were in good accordance with those of **1** except for the differences due to the conjugated side chain moiety.

In summary, glycosylation of 4-hydroxypyrone **3** and galactopyranosyl fluoride **6** provides the first reported synthetic route to C^3-pyranosyl-4-hydroxypyrone. We also observed the base-promoted isomerization of α-*C*-glycoside into the desired *β*-*C*-glycoside **8**. This two-step process affords **8** in a 61% overall yield. Furthermore, the present investigation supports the proposed C^3-*β*-galactopyranosyl-4-hydroxypyrone core structure of **1**.

Application of this method to the total synthesis of **1** is currently in progress.

Acknowledgment. We thank Dr. Tamotsu P. Niki (Gencom Corporation) for helpful discussions and Mitsubishi Pharma Corporation for providing the NMR spectra of D8646-2-6.

Supporting Information Available: Detail experimental procedure, full characterization, and copies of all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL034873K

(12) (a) Hashimoto, S.; Hayashi, M.; Noyori, R. *Tetrahedron Lett.* **1984**, *25*, 1379. (b) Andersson, F.; Fügedi, P.; Garegg, P. J.; Nashed, M. *Tetrahedron Lett.* **1986**, *27*, 3919. (c) Ito, Y.; Ogawa, T. *Tetrahedron Lett.* **1987**, *28*, 4701.

(13) (a) Lokot, I. P.; Pashkovsky, F. S.; Lakhvich, F. A. *Tetrahedron* **1999**, *55*, 4783. (b) Nagamitsu, T.; Sunazuka, T.; Obata, R.; Tomoda, H.; Tanaka, H.; Harigaya, Y.; Omura, S.; Smith, A. B., III. *J. Org. Chem.* **1995**, *60*, 8126. (c) Cook, L.; Ternai, B.; Ghosh, P. *J. Med. Chem.* **1987**, *30*, 1017.

(14) (a) Sugawara, K.; Kohno, J.; Nakanishi, N.; Hashiyama, T. *Tennen Yuki. Kagoubutsu Toronkai Koen Yoshishu.* **2000**, *42*, 661. (b) Hosoya, T.; Ohashi, Y.; Matsumoto, T.; Suzuki, K. *Tetrahedron Lett.* **1996**, *37*, 663.